BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, July 30, 2026
Home » Topics » Regulatory

Regulatory
Regulatory RSS Feed RSS

Skip the footnote, PhRMA tells FDA, advising stronger guidance for interchangeables

April 14, 2020
By Mari Serebrov
When it comes to guidance on interchangeables, the Pharmaceutical Research and Manufacturers of America (PhRMA) has some guidance for the FDA: Be more definite.
Read More

Regulatory front for April 14, 2020

April 14, 2020
The latest global regulatory news, changes and updates affecting biopharma.
Read More

Regulatory actions for April 14, 2020

April 14, 2020
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: 7 Hills, Alnylam, AVM, Epirium, Grid, Kadmon, KD Pharma, Lifemax.
Read More

Koselugo receives FDA approval for pediatric patients with NF1-related plexiform neurofibromas

April 14, 2020
FDA icons

FDA adds to EUAs for COVID-19 as Congress presses agency on serological testing

April 13, 2020
By Mark McCarty
The U.S. FDA’s routine guidance agenda may be badly disrupted by the COVID-19 outbreak, but the agency continues to pump out guidances and emergency use authorizations (EUAs) directed to the pandemic. While the FDA has included only one serological test under the diagnostic EUA paradigm, Rep. Diana DeGette penned a letter inquiring into when the agency intends to move more decisively on serological tests, arguing that the absence of action on this front endangers the nation’s economic health as well as the public’s health.
Read More

Regulatory front for April 13, 2020

April 13, 2020
The latest global regulatory news, changes and updates affecting medical devices and technologies, including: Johnson & Johnson, Takeda Pharmaceutical.
Read More

New MEK inhibitor approval delivers first NF1 therapy, PRV for Astrazeneca

April 13, 2020
By Michael Fitzhugh
Following a priority review, partners Astrazeneca plc and Merck & Co. Inc. have gained a green light from the FDA for U.S. marketing of the oral MEK1/2 inhibitor Koselugo (selumetinib), the first FDA-approved treatment for the rare genetic disorder neurofibromatosis type 1 (NF1).
Read More

Regulatory actions for April 13, 2020

April 13, 2020
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Arch Therapeutics, Cytosorbents.
Read More

Regulatory front for April 13, 2020

April 13, 2020
The latest global regulatory news, changes and updates affecting biopharma.
Read More

Regulatory actions for April 13, 2020

April 13, 2020
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Algernon, Arch, Arcturus, Ascletis, Astrazeneca, Athersys, Beigene, Can-Fite, Fennec, Hope, Merck, Predictive Biotech, Proteostasis, Ridgeback.
Read More
Previous 1 2 … 931 932 933 934 935 936 937 938 939 … 1382 1383 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 29, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 28, 2026
  • Illustration of dopamine signaling in the brain

    New schizophrenia targets challenge trial design

    BioWorld
    The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
  • Regulatory actions for July 27, 2026

    BioWorld
    Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Alfasigma,...
  • 3D representation of tumor

    AACR D3: ONM-421 shows antigen-independent tumor control

    BioWorld Science
    At the American Association for Cancer Research’s inaugural Drug Discovery and Development conference (AACR D3), Onconano Medicine Inc. presented preclinical data...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
    • Videos
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing